

Osteoarthritis Report



VDI Lab Services
 4685 Runway St. Ste K Simi Valley, CA 93063
 ph: 805-577-6742 fax: 805-426-8115

PATIENT NAME: Grover Cleveland Andersc	MRN: 1098423	VETERINARIAN:
SPECIMEN ID: 173191	DRAW DATE: 7-Dec-22	FACILITY:
SPECIES: Feline	RECEIVED DATE: 14-Dec-22	
GENDER: Male Neutered	REPORT DATE: 15-Dec-22	
AGE: 18.8	SAMPLE TYPE: Frozen Serum - LV	PH:
WEIGHT: 5.2 lb	PATIENT STAGE: unknown	FAX:
BREED: DSH	TREATMENT: unknown	

Osteoarthritis Panel

Relevant Context (provided on TRF)

<input type="checkbox"/> Corticosteroids	<input type="checkbox"/> Antibiotic	<input type="checkbox"/> Suspected Mass	<input type="checkbox"/> Hypercalcemia
<input type="checkbox"/> NSAIDs	<input type="checkbox"/> Anemia	<input type="checkbox"/> Enlarged Node	<input type="checkbox"/> B12 Deficiency
<input type="checkbox"/> Chemotherapy	<input type="checkbox"/> GI Signs	<input type="checkbox"/> Fever	<input type="checkbox"/> Known Disease

HA

Positive

35.1

ng/mL

Normal: < 35
Positive: ≥ 35

HPT

Moderate


183.3

mg/L

Decreased (D): < 25
Normal: 25 - 64.9
Mild Inflamm (m): 65 - 140
Mod Inflamm (M): 140-225
High Inflamm (H): ≥ 225.1

Intpretative Comment

Patient values for HA are elevated consistent with degenerative joint disease (OA, IVDD). Inflammation (elevated HPT) can be encountered in these patients, particularly those not being treated with anti-inflammatory medication (eg, NSAIDs). However, inflammation is typically mild and other concurrent sources of inflammation should be evaluated. HA may be elevated in wounds, ACL/CCL injury, severe liver disease, and in patients being treated with PSGAG (ie, Adequan).



Additional Reviewer Comments - need consult? email consult@vdiilab.com

code 23662

All comments are general in nature and in absence of detailed knowledge of patient status or treatment.
 For case-specific consultations, please contact VDI.

Reviewer: RR



Hyaluronic Acid Report

PATIENT NAME: Grover Cleveland Anders **MRN:** 1098423
SPECIMEN ID: 173191 **DRAW DATE:** 7-Dec-22
SPECIES: Feline **RECEIVED DATE:** 14-Dec-22
GENDER: Male Neutered **REPORT DATE:** 15-Dec-22
AGE: 18.8 **SAMPLE TYPE:** Frozen Serum - LV
WEIGHT: 5.2 lb
BREED: DSH

VETERINARIAN:
FACILITY:
PH:
FAX:


Hyaluronic Acid (ng/mL)

Positive

35.1

Normal: <35
Positive: ≥35

Change from Previous



Patient History

ID	Date	Result ng/mL

Interpretive Comments - need consult? email consult@vdi lab.com

Hyaluronic acid is above the reference interval and is indicative of degenerative joint disease, however, severe liver disease can elevate hyaluronic acid. Evaluate liver function. sHA may be elevated in wounds, ACL/CCL injury, severe liver disease, and in patients being treated with PSGAG (ie, Adequan) and oral HA supplement. Supplementing with oral HA has been shown to improve joint function. Follow recommendations below.

Phases of Degenerative Joint Disease			
Pre-/Early	Mild	Moderate	Severe
HA: Serum HA (sHA) below the positive cutoff. HA is being produced and maintained inside the joints. HPT: Typically absent, except in IMPA	HA: sHA above positive cutoff. HA is being produced but early degeneration allows some HA to leak into peripheral blood. HPT: Typically absent, except in IMPA.	HA: Moderate to high levels of sHA increasing with disease severity. HA is being produced but significant degeneration causes HA to leak into peripheral blood. Joint cushioning & lubrication is negatively affected. HPT: Mild inflammation may be present in moderate OA, IVDD, due to mechanical damage inside the joint. IMPA presents with elevated HPT.	HA: High to declining sHA levels. In severe DJD, chondrocyte cell death limits the production of HA. HA that is produced is leaked into the peripheral blood. Joint cushioning & lubrication is severely affected. HPT: Moderate to high inflammation may be present in OA, IVDD. Elevated HPT in IMPA.
No clinical signs present, but cat may be predisposed or at high risk of DJD.	Cat may begin showing some stiffness or rigidity. Doesn't interfere with day-to-day activity, but gait may change during exercise.	Cat may be showing noticeable pain, stiffness, lethargy with cat being uncomfortable, crying, or becoming increasingly reluctant to walk around.	Cat is typically reluctant to walk, go to the bathroom, or perform daily activities due to increased pain that has become unbearable.

Supplementation Guide

Dosing Guidelines - Twice Per Day				
PRODUCT NAME	Active Ingredient	PRODUCT STRENGTH	# of Pumps	mL/Day
Trixsyn® Feline Hyaluronan	Sodium Hyaluronate	4 mg/mL	N/A	1mL, twice per day
Other	_____			